Exercise of warrants

RNS Number : 1089E
OptiBiotix Health PLC
09 March 2022
 

OptiBiotix Health plc

("OptiBiotix" or the "Company ")

 

Exercise of warrants

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, ann o un ces   that it has received notification to exercise warrants over 60 new ordinary shares of 2p each in the capital of the Company ("Ordinary Shares"). The exercise price of the warrants was 8p per share, providing the Company with proceeds of £4.80. 

 

Application will be made for the 60 new Ordinary Shares to be admitted to trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any ordinary shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

 

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

 

 

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti




Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEZZGGFMRNGZZZ
UK 100

Latest directors dealings